Schedule 13G ownership disclosure

Spyre Therapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 00773J202

Event date: 2025-04-24

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • TANG CAPITAL MANAGEMENT, LLC

    Shares: 3,200,000.00 · Class: 5.3%

  • KEVIN TANG

    Shares: 3,200,000.00 · Class: 5.3%

  • TANG CAPITAL PARTNERS, LP

    Shares: 1,799,658.00 · Class: 3.0%

  • TANG CAPITAL PARTNERS INTERNATIONAL, LP

    Shares: 1,400,342.00 · Class: 2.3%

  • TANG CAPITAL PARTNERS III, INC

    Shares: 0.00 · Class: 0.0%

  • TANG CAPITAL PARTNERS IV, INC

    Shares: 0.00 · Class: 0.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001214659-25-006773
Form type
SCHEDULE 13G
Filer
Spyre Therapeutics, Inc.
CIK
CIK 1636282
Filed
May 01, 2025
Reporting period
Apr 24, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub